Activation of miR-21 by STAT3 induces proliferation and suppresses apoptosis in nasopharyngeal carcinoma by targeting PTEN gene

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Ou, Hesheng ^a   Li, Yumei ^a   Kang, Min ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; MESSENGER RNA; MICRORNA 21; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; STAT3 PROTEIN; MICRORNA; MIRN21 MICRORNA, HUMAN;

3' UNTRANSLATED REGION; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL LINE; CANCER INHIBITION; CANCER TISSUE; CELL ASSAY; CELL PROLIFERATION; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DNA FRAGMENTATION; ENZYME ACTIVITY; FEMALE; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUCIFERASE ASSAY; LYMPH NODE METASTASIS; MALE; MOUSE; NASOPHARYNX CARCINOMA; NICK END LABELING; NONHUMAN; PROTEIN EXPRESSION; PTEN GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STAT3 GENE; TUMOR VOLUME; UPREGULATION; WESTERN BLOTTING; AGED; ANIMAL; CANCER STAGING; CASE CONTROL STUDY; CELL TRANSFORMATION; DISEASE MODEL; GENE EXPRESSION; GENETICS; METABOLISM; METASTASIS; MIDDLE AGED; NASOPHARYNX TUMOR; PATHOLOGY; PHOSPHORYLATION; RNA INTERFERENCE; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

ADULT; AGED; ANIMALS; APOPTOSIS; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM METASTASIS; NEOPLASM STAGING; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RNA INTERFERENCE; STAT3 TRANSCRIPTION FACTOR; TRANSCRIPTIONAL ACTIVATION; TUMOR BURDEN;

EID: 84909606237     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0109929     Document Type: Article

References (70)

1. Jeannel D, Bouvier G, Huber A (1999) Nasopharyngeal carcinoma: an epidemiological approach to carcinogenesis. Cancer Surv 33:125-155.
2. Parkin DM, Bray F, Ferlay J, Pisani P (2002) Global cancer statistics. CA Cancer J Clin 55: 74-108.
3. Yuan JM, Wang XL, Xiang YB, Gao YT, Ross RK, et al. (2000) Preserved foods in relation to risk of nasopharyngeal carcinoma in Shanghai, China. Int J Cancer 85: 358-363.
4. Liebowitz D (1994) Nasopharyngeal carcinoma: the Epstein-Barr virus association. Semin Oncol 21: 376-381.
5. Lo KW, Huang DP (2002) Genetic and epigenetic changes in nasopharyngeal carcinoma. Semin Cancer Biol 12: 451-462.
6. Ambros V (2003) MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell 13: 673-676.
7. Esquela-Kerscher A, Slack FJ (2006) Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269.
8. Chan JA, Krichevsky AM, Kosik KS (2005) MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 65: 6029-6033.
9. Fulci V, Chiaretti S, Goldoni M, Azzalin G, Carucci N, et al. (2007) Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood 109: 4944-4951.
10. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, et al. (2006) Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9: 189-198.
11. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, et al. (2005) MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65: 7065-7070.
12. Meng F, HensonR, Wehbe-Janek H, GhoshalK, Jacob ST, et al. (2007) MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133: 647-658.
13. Papagiannakopoulos T, Shapiro A, Kosik KS (2008) MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. Cancer Res 68: 8164-8172.
14. Hiyoshi Y, Kamohara H, Karashima R, Sato N, Imamura Y, et al. (2009) MicroRNA-21 regulates the proliferation and invasion in esophageal squamous cell carcinoma. Clin Cancer Res 15:1915-1922.
15. Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A, et al (2008) Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem 283: 1026-1033.
16. Si ML, Zhu S, Wu H, Lu Z, Wu F, et al. (2007) miR-21-mediated tumor growth. Oncogene 26: 2799-2803.
17. Zhu S, Wu H, Wu F, Nie D, Sheng S, et al. (2008) MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res 18: 350-359.
18. Demaria M, Misale S, Giorgi C, Miano V, Camporeale A, et al. (2012) STAT3 can serve as a hit in the process of malignant transformation of primary cells. Cell Death Differ 19: 1390-1397.
19. Demaria M, Poli V (2012) Pro-malignant properties of STAT3 during chronic inflammation. Oncotarget 3: 359-360.
20. Giraud AS, Menheniott TR, Judd LM (2012) Targeting STAT3 in gastric cancer. Expert Opin Ther Targets 16: 889-901.
21. Shodeinde AL, Barton BE (2012) Potential use of STAT3 inhibitors in targeted prostate cancer therapy: future prospects. Onco Targets Ther 5: 119-125.
22. Pensa S, Regis G, Boselli D, Novelli F, Poli V (2009) STAT1 and STAT3 in Tumorigenesis: Two Sides of the Same Coin? JAK-STAT Pathway in Disease 100.
23. Ai T, Wang Z, Zhang M, Zhang L, Wang N, et al. (2012) Expression and prognostic relevance of STAT3 and cyclin D1 in non-small cell lung cancer. Int J Biol Markers 27: 132-138.
24. Barré B, Avril S, Coqueret O (2003) Opposite regulation of myc and p21waf1 transcription by STAT3 proteins. J Biol Chem 278: 2990-2996.
25. Ettl T, Stiegler C, Zeitler K, Agaimy A, Zenk J, et al. (2012) EGFR, HER2, survivin, and loss of pSTAT3 characterize high-grade malignancy in salivary gland cancer with impact on prognosis. Hum Pathol 43: 921-931.
26. Qu C, Liang Z, Huang J, Zhao R, Su C, et al. (2012) MiR-205 determines the radioresistance of human nasopharyngeal carcinoma by directly targeting PTEN. Cell Cycle 11: 785-796.
27. Kurose K, Zhou X-P, Araki T, Cannistra S, Maher E, et al. (2001) Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclinD1 expression, in primary epithelial ovarian carcinomas. Am J Pathol 158: 2097-2106.
28. Panigrahi AR, Pinder SE, Chan SY, Paish EC, Robertson JFR, et al. (2004) The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome. J Pathol 204: 93-100.
29. Netto G, Epstein J (2010) Theranostic and prognostic biomarkers: genomic applications in urological malignancies. Pathology 42: 384-394.
30. Azim H, Azim H, Escudier B (2010) Targeting mTOR in cancer: renal cell is just a beginning. Target Oncol 5: 269-280.
31. Xu J, Deng X, Tang M, Li L, Xiao L, et al. (2013) Tyrosylprotein sulfotransferase-1 and tyrosine sulfation of chemokine receptor 4 are induced by Epstein-Barr virus encoded latent membrane protein 1 and associated with the metastatic potential of human nasopharyngeal carcinoma. PLoS One 8: e56114.
32. Yan L, Kang M, Qin Z, Zhang W, Li Y, et al. (2013) An intronic miRNA regulates expression of the human endothelial nitric oxide synthase gene and proliferation of endothelial cells by a mechanism related to the transcription factor SP-1. PLoS One 8: e70658.
33. Wang LH, Kim SH, Lee JH, Choi YL, Kim YC, et al. (2007) Inactivation of SMAD4 tumor suppressor gene during gastric carcinoma progression. Clin Cancer Res 13: 102-110.
34. Chern CJ, Beutler E (1976) Biochemical and electrophoretic studies of erythrocyte pyridoxine kinase in white and black Americans. Am J Hum Genet 28: 9-17.
35. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, et al. (2005) Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 33: e179.
36. Ou H, Shen YH, Utama B,Wang J,Wang X, et al. (2005) Effect of nuclear actin on endothelial nitric oxide synthase expression. Arterioscler Thromb Vasc Biol 25: 2509-2514.
37. Wu L, Li Z, Zhang Y, Zhang P, Zhu X, et al. (2008) Adenovirus-expressed human hyperplasia suppressor gene induces apoptosis in cancer cells. Mol Cancer Ther 7: 222-232.
38. Melo SA, Ropero S, Moutinho C, Aaltonen LA, Yamamoto H, et al. (2009) A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function. Nat Genet 41: 365-370.
39. Yan LX, Huang XF, Shao Q, Huang MY, Deng L, et al. (2008) MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA 14: 2348-2360.
40. Yang M, Shen H, Qiu C, Ni Y, Wang L, et al. (2013) High expression of miR-21 and miR-155 predicts recurrence and unfavourable survival in non-small cell lung cancer. Eur J Cancer 49: 604-615.
41. Markou A, Tsaroucha EG, Kaklamanis L, Fotinou M, Georgoulias V, et al. (2008) Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RTPCR. Clin Chem 54: 1696-1704.
42. Cho WC, Chow AS, Au JS (2009) Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation. Eur J Cancer 45: 2197-2206.
43. Seike M, Goto A, Okano T, Bowman ED, Schetter AJ, et al. (2009) MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc Natl Acad Sci USA 106: 12085-12090.
44. Teng Y, Manavalan TT, Hu C, Medjakovic S, Jungbauer A, et al. (2013) Endocrine Disruptors Fludioxonil and Fenhexamid Stimulate miR-21 Expression in Breast Cancer Cells. Toxicol Sci 2013; 131: 71-83.
45. Kanaan Z, Rai SN, Eichenberger MR, Roberts H, Keskey B, et al. (2012) Plasma miR-21: a potential diagnostic marker of colorectal cancer. Ann Surg 256: 544-551.
46. Wu CW, Ng SS, Dong YJ, Ng SC, Leung WW, et al. (2012) Detection of miR-92a and miR-21 in stool samples as potential screening biomarkers for colorectal cancer and polyps. Gut 61: 739-745.
47. Bihrer V, Waidmann O, Friedrich-Rust M, Forestier N, Susser S, et al. (2011) Serum microRNA-21 as marker for necroinflammation in hepatitis C patients with and without hepatocellular carcinoma. PLoS One 6: e26971.
48. Li T, Li RS, Li YH, Zhong S, Chen YY, et al. (2012) miR-21 as an independent biochemical recurrence predictor and potential therapeutic target for prostate cancer. J Urol 187: 1466-1472.
49. Yang CH, Yue J, Fan M, Pfeffer LM (2010) IFN induces miR-21 through a signal transducer and activator of transcription 3-dependent pathway as a suppressive negative feedback on IFN-induced apoptosis. Cancer Res 70: 8108-8116.
50. Moriyama T, Ohuchida K, Mizumoto K, Yu J, Sato N, et al. (2009) MicroRNA-21 modulates biological functions of pancreatic cancer cells including their proliferation, invasion, and chemoresistance. Mol Cancer Ther 8: 1067-1074.
51. Catto JW, Miah S, Owen HC, Bryant H, Myers K, et al. (2009) Distinct microRNA alterations characterize high-and low-grade bladder cancer. Cancer Res 69: 8472-8481.
52. Alder H, Taccioli C, Chen H, Jiang Y, Smalley KJ, et al. (2012) Dysregulation of miR-31 and miR-21 induced by zinc deficiency promotes esophageal cancer. Carcinogenesis 33: 1736-1744.
53. Yamanaka Y, Tagawa H, Takahashi N, Watanabe A, Guo YM, et al. (2009) Aberrant overexpression of microRNAs activate AKT signaling via downregulation of tumor suppressors in natural killer-cell lymphoma/leukemia. Blood 114: 3265-3275.
54. Liu M, Wu H, Liu T, Li Y, Wang F, et al. (2009) Regulation of the cell cycle gene, BTG2, by miR-21 in human laryngeal carcinoma. Cell Res 19: 828-837.
55. Li J, Huang H, Sun L, Yang M, Pan C, et al. (2009) MiR-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor. Clin Cancer Res 15: 3998-4008.
56. Zaman MS, Shahryari V, Deng G, Thamminana S, Saini S, et al. (2012) Upregulation of microRNA-21 correlates with lower kidney cancer survival. PLoS One 7: e31060.
57. Gao W, Shen H, Liu L, Xu J, Xu J, et al. (2011) MiR-21 overexpression in human primary squamous cell lung carcinoma is associated with poor patient prognosis. Cancer Res Clin Oncol 137: 557-566.
58. Gao W, Yu Y, Cao H, Shen H, Li X, et al. (2010) Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis. Biomed Pharmacother 64: 399-408.
59. Knouf EC, Garg K, Arroyo JD, Correa Y, Sarkar D, et al. (2012) An integrative genomic approach identifies p73 and p63 as activators of miR-200 microRNA family transcription. Nucleic Acids Res 40: 499-510.
60. Dai B, Meng J, Peyton M, Girard L, Bornmann WG, et al. (2011) STAT3 mediates resistance to MEK inhibitor through microRNA miR-17. Cancer Res 71: 3658-3668.
61. Wang B, Hsu SH, Frankel W, Ghoshal K, Jacob ST (2012) Stat3-mediated activation of microRNA-23a suppresses gluconeogenesis in hepatocellular carcinoma by down-regulating glucose-6-phosphatase and peroxisome proliferator-activated receptor gamma, coactivator 1 alpha. Hepatology 56: 186-197.
62. Yan L, Hao H, Elton TS, Liu Z, Ou H (2011) Intronic microRNA suppresses endothelial nitric oxide syntahse expression and endothelial cell proliferation via inhibition of stat3 signaling. Mol Cell Biochem 357: 9-19.
63. Li J, Yen C, Liaw D, Podsypanina K, Bose S, et al. (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943-1947.
64. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, et al. (1997) Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15: 356-362.
65. Leslie NR, Bennett D, Lindsay YE, Stewart H, Gray A, et al. (2003) Redox regulation of PI 3-kinase signalling via inactivation of PTEN. EMBO J 22: 5501-5510.
66. Stewart AL, Mhashilkar AM, Yang XH, Ekmekcioglu S, Saito Y, et al. (2002) PI3K blockade by Ad-PTEN inhibits invasion and induces apoptosis in radial growth phase and metastatic melanoma cells. Mol Med 8: 451-461.
67. Castellino RC, Durden DL (2007) Mechanisms of disease: the PI3K-Akt-PTEN signaling node-an intercept point for the control of angiogenesis in brain tumors. Nat Clin Pract Neurol 3: 682-693.
68. Maehama T, Dixon JE (1998) The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3, 4, 5-trisphosphate. J Biol Chem 273: 13375-13378.
69. Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, et al. (2006) Involvement of human microRNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 130: 2113-2129.
70. Vogt PK, Gymnopoulos M, Hart JR (2009) PI 3-kinase and cancer: changing accents. Curr Opin Genet Dev 19: 12-17.